News & events

News & events

Filter by:
  • News

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it...
  • News

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the...
  • Conferences & Events

VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces...
  • Scientific publications

Coagulation assays for assessing direct FXa inhibitor oral anticoagulant reversal effect

  • Conferences & Events

VarmX to Present Two Abstracts on Lead Compound, VMX-C001, at ISTH 2023 Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces...
  • News

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it...
  • News

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the...
  • News

VarmX appoints Paul Roos as Chief Financial Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the...
  • Scientific publications

Preclinical safety and toxicokinetics of VMX-C001 – an intravenous bypassing agent for factor Xa inhibitors

  • News

VarmX to Present New Data at the 2022 ISTH Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announced it...
  • News

First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001

VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio